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 Introduction 
On May 19, 2016, the US Food and Drug Administration (FDA) hosted a public 
workshop, entitled ‘‘Mechanistic Oral Absorption Modeling and Simulation for Formulation 
Development and Bioequivalence Evaluation’’ [1]. The topic of mechanistic oral absorption 
modeling, which is one of the major applications of physiologically based pharmacokinetic 
(PBPK) modeling and simulation, focuses on predicting oral absorption by mechanistically 
integrating gastrointestinal transit, dissolution, and permeation processes, incorporating systems, 
drug active pharmaceutical ingredient (API) and the product information, into a systemic 
mathematical whole-body framework [2].  
Dr. Kathleen Uhl, Director of the Office of Generic Drugs (OGD), opened the discussion. 
In her opening remarks, Dr. Uhl highlighted the potential impact and benefits of implementing 
the innovative tool of mechanism-based modeling and simulation in the context of generic drug 
product development and review for both industry and the regulatory agency. With all these 
efforts, mechanism-based modeling and simulation can potentially improve the first cycle 
approval rate of generic drug products and further accelerate public access to generic products. 
Dr. Liang Zhao (FDA, workshop chair), indicated areas where modeling and simulation 
practices have been employed for both generic and new drugs in the regulatory setting. 
Specifically, in the generic drug program, internal efforts utilizing modeling and simulation to 
inform regulatory decision making are significant[1]. Although oral absorption modeling has 
been used intensively within OGD, there is currently a lack of modeling and simulation reports 
in ANDA submissions.  Dr. Zhao also highlighted the PBPK reviews in New Drug Applications 
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(NDAs) including the numbers and impacts on product labels. At the end, Dr. Zhao concluded 
his introduction by emphasizing the areas where mechanism-based absorption models can have 
high impact. 
Plenary and Panel Discussion Sessions 
Dr. John Duan, and Dr. Xinyuan Zhang, both from FDA, shared their experience in 
utilizing physiologically based absorption modeling in new drug and generic drug regulatory 
activities, respectively. Dr. Duan’s presentation first set the stage for the application of 
mechanistic oral absorption model in biopharmaceutics review by focusing on the concept of 
‘patient-centric quality’ and the ‘bridging’ role of ‘biopharmaceutics’ in product development, 
approval, and product lifecycle management. Although absorption modeling and simulation 
(M&S) currently only accounts for a small portion of total PBPK modeling submissions, it has 
great potential in biopharmaceutics applications. Three examples were enumerated where 
absorption M&S was applied to select clinically meaningful dissolution test method, to define 
the dissolution and particle size specifications, and to understand the impact of quality attributes 
on product performance by performing multi-dimensional parameter sensitivity analysis (Table 
1).  In addition, common limitations in regulatory submissions regarding mechanistic oral 
absorption models and simulations were indicated, such as model exercises were performed but 
not being fully utilized in submission; detailed information was not provided; model was not 
fully verified; model files were not provided; rationale was not clear; and justifications were not 
reasonable.  Based on these, Dr. Duan listed the necessary elements for mechanistic oral 
absorption models in regulatory submissions including detailed model information (input 
parameters, optimized parameters, software type and version, logical description of model 
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building and validation process, executable model files, and simulation conditions), appropriate 
justifications for input parameters (sources and selection, optimized parameters, raw data to 
support the model verification & correlation), and rationales to support the request for regulatory 
actions. Dr. Duan concluded his presentation by a forward-looking view to meet the challenge in 
drug development.   
Subsequently, Dr. Zhang provided an update on the regulatory activities based on absorption 
M&S in OGD with two case examples, and an update on the Generic Drug User Fee 
Amendments (GDUFA) research efforts to modernize the toolset of oral absorption M&S.  In the 
past decade, absorption M&S tools have been used actively to address a wide range of scientific 
questions in OGD [2-7].  One example presented was the evaluation of the impact of slow 
dissolution in a specific pH condition on BE for warfarin sodium tablets. In this example, a 
human BE study was conducted to confirm the model prediction and the model prospectively 
predicted the in vivo BE outcome. However, not every simulation can be confirmed by an in 
vivo study. In this case, communicating the results and conclusions to non-modelers in way that 
could have informed a decision that the in vivo study was not needed, and not the modeling task 
itself, was challenging.  Accumulating positive predictive experience of absorption modeling can 
help communicate the value of proactive modeling to pharmaceutical decision making.  The 
second case example involved investigating the impact of proton pump inhibitors on BE for 
prasugrel HCl tablets and fingolimod capsules (Table 1). Both examples helped define product 
quality specifications.  Dr. Zhang concluded that there are existing challenges in predicting oral 
absorption. Therefore, further research efforts and scientific studies including GDUFA funded 
research are needed to advance and sharpen the relevant toolsets. 
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Dr. Filippos Kesisoglou (Merck), and Dr. Jasmina Novakovic (Apotex) presented 
applications of absorption modeling and simulation from the new drug and generic drug industry 
perspectives, respectively. Dr. Kesisoglou provided six case examples (Table 1) covering a wide 
range of applications in new drug development, including guiding early formulation 
development, projection of BE outcomes, impact of the API form on bioavailability, food effect 
projection, and development of mechanism-based in vitro in vivo correlations (IVIVCs) [8]. In 
Dr. Novakovic’s presentation, multiple stages in the generic drug development and life-cycle 
management were illustrated where PBPK absorption modeling plays a pivotal role for the 
reference product characterization, quality target product profile establishment, formulation 
design and product development, defining bio-indicative dissolution test conditions and 
clinically meaningful specification limits. She provided a case example where PBPK absorption 
modeling was used to refine a formulation development strategy (Table 1).  
The morning session was concluded with Dr. Gordon Amidon (University of Michigan), 
the inventor of the Biopharmaceutics Classification System (BCS). He emphasized that the key 
to accurate predictions is the model input.  He pointed out that our current dissolution 
methodology, e.g. USP methods, is a quality control methodology.  Further, our biorelevant 
dissolution media are only approximate.   He emphasized that we need more directly measured 
human physiological variables, including mean, median and statistical ranges and probability 
distribution or density function to model truly predictive in vivo absorption.   Such in vivo 
measurements need to be performed under typical dosing conditions, fasted and fed, and BE trial 
conditions and an in vitro dissolution methodology needs to incorporate those physiological 
variable ranges.  He noted that BCS class and the recently proposed subclasses[9] e.g. acid, base, 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
neutral,  is a starting point for developing a predictive dissolution methodology.  Finally, he 
noted that a predictive dissolution methodology would be an extremely valuable tool for a 
formulation scientist in developing an oral drug product and would be very useful in determining 
critical variables for quality by design (QbD) and process analytical technology (PAT) purposes.     
The afternoon session consisted of three presentations from software developers, Dr. 
Masoud Jamei (Simcyp), Dr. Viera Lukacova (SimulationsPlus), and Dr. Thomas Eissing 
(Bayer), and one presentation from OrBiTo (by Dr. Filippos Kesisoglou). Echoing Dr. Amidon’s 
talk, all three presenters (Dr. Jamei, Dr. Lukacova, and Dr. Eissing) provided case examples 
utilizing PBPK absorption models to link in vitro dissolution with in vivo performance and again 
exemplified the importance of getting in vivo predictive in vitro dissolution as the appropriate 
model input (Table 1). Modeling of in vitro dissolution experiments was also mentioned as a tool 
to improve in vivo translation. Physiologically based IVIVC was discussed in all three 
presentations with message that the key advantage, compared to conventional IVIVC, is that the 
deconvoluted input profile is the predicted in vivo dissolution, and not the absorption fraction 
which is often confounded by dissolution, permeability, and gut metabolism processes. Dr. Jamei 
advocated incorporating physiologically realistic fluid dynamics and luminal fluid volumes into 
absorption models. Finally, he discussed the opportunities and challenges including knowledge 
gaps in systems data and absorption mechanisms, inter-occasion variability, colonic absorption, 
and education.  Dr. Lukacova followed with a case where post approval process change resulted 
in different particle size distributions for the new lots for a specific drug product. Waiver of in 
vivo study was granted based on PBPK absorption modeling, parameter sensitivity analysis for 
the particle size distribution, and virtual BE simulations. Dr. Eissing provided several case 
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examples where PBPK absorption modeling has been successfully used to bridge in vitro particle 
size distribution or dissolution with in vivo performance, characterize PK variability, food effect 
prediction, and regional absorption prediction. Finally, Dr. Eissing introduced population PBPK 
where variability and uncertainties of PBPK parameters and predictions could be assessed given 
model structure, prior knowledge, and combining intravenous (i.v.) and per os (p.o.) data sets. 
He also argued for full transparency of models including structure and parameterization for 
general physiology as well as specific application to allow for a rigorous scientific assessment. 
The OrBiTo project vision is to “transform our ability to accurately predict the in vivo 
performance of oral drug products across all stages of drug development”. Dr. Filippos 
Kesisoglou, on behalf of OrBiTo gave an overview of the mission, vision, and the most recent 
achievements of the project. Two examples (Table 1) were presented to highlight the urgent need 
of identifying in vivo predictive/biorelevant dissolution testing in establishing a connection 
between drug dissolution and clinical performance. 
The panel members consisted of speakers and internal FDA experts. The questions and 
major discussion points are summarized in Table 2. Briefly, many successful cases were 
presented in each presentation. The most frequently presented applications were to define quality 
related product specification (such as particle size distribution, and in vitro dissolution). Food 
effect prediction, mechanistic IVIVC, and drug-drug interactions (DDIs) associated with gastric 
pH modifications, were also of significant interest due to the potential to reduce unnecessary 
studies in development, and facilitated biowaivers. However, the confidence levels in each area 
have to be evaluated on a case-by-case basis.    
Conclusions 
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Heated discussion was generated around the questions (Table 2), and the panelist 
expressed different opinions in response to the questions, such as the level of confidence in 
prediction of food effect and proton pump inhibitor (PPI) effects on absorption. The panel 
members also reached consensus regarding the level of confidence in each area that it has 
to be examined on a case-by-case basis and no general conclusions can be drawn at the 
moment. 
In the closing remarks, Dr. Robert Lionberger (OGD) emphasized that mechanism-based 
oral absorption M&S is a critical core technology area for the generic drug review function at 
FDA, but is also a knowledge gap for OGD. There is broad interest across the Center for Drug 
Evaluation and Research (CDER) and FDA in continuously advancing these tools.  
 
Supplemental Materials:  
Table S1: M&S Impact Various Regulatory Activities in OGD (4/1/15 to 4/1/16)  
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Table 1: Summary of case examples using absorption modeling and simulation in each presentation  
Representative  Case examples of absorption modeling applications  
Biopharm/Office of 
Pharmaceutical 
Quality 
• Identify clinically relevant dissolution method (pH 2 vs. pH 6.8) for an 
immediate-release (IR) product 
• Define dissolution and particle size distribution specifications for a 
delayed-release enteric coated product 
• Explore the impact of uncertainty in estimated parameters on model 
predictions and parameters of interest using multidimensional sensitivity 
analyses 
OGD • Investigate the impact of slower drug release from the drug product in 
acidic media and the change in a critical product attribute on warfarin 
pharmacokinetics (PK) 
• Evaluate the impact of proton pump inhibitors (PPIs) on bioequivalence 
(BE) of generic prasugrel HCl tablets and fingolimod capsules to their 
brand name products 
Innovator company • Guide development of a formulation that produces target exposure and is 
less sensitive to the change in stomach pH  
• Investigate the dissolution impact on PK and BE for enteric-coated beads 
of a BCS Class 1 compound 
• Identify clinically relevant dissolution method (pH 2 vs. pH 4.5 and 6.8) 
for a BCS Class 2 weak base compound 
• Assess potential risks from salt to base conversion as a function of 
stomach pH for a weak base BCS Class 2 drug 
• Predict food effect for a weak base BCS Class 1 drug 
• Predict PK of new formulations for a BCS Class 2 drug using absorption 
modeling based IVIVC and incorporating regional dependent absorption 
Generic company • Characterize the reference listed drug (RLD) for a BCS Class 4 product 
and design generic product development strategy 
• Identify bio-indicative dissolution test conditions and clinically relevant 
specification limits for a BCS Class 1 extended-release (ER) product  
• Justify waiver of in vivo studies for intermediate strengths using verified 
level A absorption model-based IVIVC  
• Define the boundaries for release rate controlling polymers based on bio-
indicative dissolution method identified using absorption modeling 
Academia  • Impact of motility phase dependent gastric emptying and its variation on 
PK profiles and BE trials (cimetidine, and viral compounds) 
• Impact of in vitro dissolution on PK prediction (in vivo predictive 
dissolution) 
Tool developer – 
Simcyp 
• Explore the impact of in vitro dissolution fitting methods, optimization 
and weighting schemes, gastric emptying, and factoring population 
variability on mechanistic IVIVC model predictions/development of 
metoprolol ER formulations and predict their PK in CYP2D6 poor 
metabolizers 
•  Determine dissolution specifications for a tramadol ER formulation 
• Assess therapeutic equivalence for ibuprofen IR products using 
absorption / PBPK /pharmacodynamic (PD) modeling 
• Extrapolate formulation assessment from adult to paediatric populations 
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• Predict and understand food effects for multiple compounds 
Tool developer – 
SimulationsPlus 
• Develop IVIVCs to predict PK for BCS Class 1 ER products, risperidone 
(BCS Class 2) IR tablets 
• Develop virtual BE trials to establish dissolution specification 
• Understand food effect using oral absorption modeling 
• Assess the effect of particle size on API exposure for an IR formulation 
for which a biowaiver request was granted 
Tool developer -- 
PKsim 
• Integrate in vitro dissolution data to predict PK for various dosage forms 
• Identify the source of variability for diclofenac enteric-coated tablets and 
furosemide tablets 
• Predict the influence of the particle size on the rate and extent of 
absorption for cilostazol under both fasted and fed conditions in dogs  
• Predict food effect for a test drug IR tablets, regional absorption for its 
granules, and PK for its controlled-release gastrointestinal therapeutic 
system formulation 
• Predict grapefruit juice induced food-drug interaction for nifidepine IR 
formulations 
• Predict indomethacin exposure after oral administration in preterm 
neonates 
OrBiTo • Predict active pharmaceutical ingredient (API) dissolution based on 
particle size distribution (PSD) 
• Predict first in human (FIH) PK based on API PSD   
• Incorporate in vitro dissolution profiles in the model to define API PSD 
specifications 
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Table 2: Summary of panel questions, and discussions 
Questions Discussions 
In which areas do we 
have the highest 
confidence in using 
PBPK absorption 
modeling? 
• Solubility (vs. pH) profile, particle size, and in vitro dissolution are three 
parameters that have been presented in multiple examples from the 
presentations. 
• Parameter sensitivity analysis is a commonly used procedure in model 
assessment and application to allow us increasing confidence on well 
described parameters. Yet the interplay or correlation between parameters 
should be taken into consideration. 
• Different opinions were expressed on the level of confidence in prediction 
of food effect and proton pump inhibitor (PPI) effects on absorption. 
Although the prediction accuracy was not always satisfactory, there were 
successful case examples of food effect and PPI effect prediction in the 
literature, which should not be discounted. 
• PBPK modeling is a very resource intensive process, and, therefore, should 
be reserved for high-risk products. However, it was indicated that models 
helped understand and explain to formulation groups and clinical colleagues 
mechanistically and explicitly product performance of low-risk drug 
products. 
Do we have enough 
experience and 
confidence in 
applying PBPK 
absorption models to 
support regulatory 
applications? 
• For specific cases, the panel agreed that PBPK absorption modeling can 
help understand what the risks are when widening the BCS Class 3 
biowaiver criteria (such as proposed longer dissolution time than very 
rapidly dissolve and/or different excipients).   
• On to the level of confidence in each area, the panel members agreed that it 
has to be examined on a case-by-case basis and no general conclusions can 
be drawn at the moment. 
• Another question triggered by the aforementioned discussion was how 
much model and extrapolative step qualification is needed to give scientists 
enough confidence to trust the model prediction. This question remained 
open to further discussion after the workshop. 
What are the gaps in 
the prediction and 
how to close them 
through research? 
• Besides the gaps in scientific understanding, there is also a confidence gap 
in what people believe in PBPK model prediction and what our assessment 
of the model is. 
• Scientific gaps identified included excipient effects, biopharmaceutics 
knowledge, and/or biorelevant dissolution methodology on a 
compound/product basis, the lack of in vivo data on the dissolution of drug 
products in the GI tract, and local permeability in the GI tract. 
• Publishing and developing databases and repositories were suggested as 
ways to share the knowledge acquired by stakeholders involved in the 
PBPK model development process. 
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